Equipped with state-of-the-art equipment, the Scientific Center for Innovative Medicines of VolgSMU has become a platform that unites scientists, pharmaceutical companies and research laboratories to conduct comprehensive research aimed at creating new medicines.

NCIL specialists develop medicines of various pharmacological groups, including those for the treatment of cardiovascular, metabolic, neurological and infectious diseases. A testing center is organized on the basis of the center, which is being prepared for GLP accreditation, which will allow in the future to carry out work in accordance with international standards of good laboratory practice.

« An important feature of our center is its openness to cooperation. We offer pharmaceutical companies and research organizations to use the NCLS infrastructure to conduct contract research. This approach makes it possible to combine scientific and industrial potential, speeding up the process of creating and implementing innovative medicines», - said Vladimir Shkarin.

An antidiabetic drug has become a landmark example in this direction Dipiaron. Thanks to the cooperation with the Chemical Diversity Research Institute LLC, as well as highly professional specialists and the support of the Unicorn Capital investment fund, the development of VolgSMU scientists begins clinical trials as a potentially first-in-class drug.

- There is just as much work to be done at NCILSE as there is direction. We have all the technological conditions for successful drug development Ivan Tyurenkov emphasized.

Scientists of the NCCLS note that currently there is an unprecedented increase in the incidence of diabetes mellitus. However, a significant proportion of patients remain undiagnosed. They do not receive treatment and have a high risk of developing complications.

- There are no similar developments in world clinical practice. The drug developed by VSMU scientists can become a valuable addition to the combination therapy of diabetes, improving the prognosis of the course of the disease- said Denis Babkov, Director of the Scientific Research Center of the Volga State Medical University. 

Currently, recruitment of patients for clinical and clinical trials has already begun.spytanij.

A source: https://pikabu.ru/